Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study of the Safety and Efficacy of Autologous Immunoregulatory Dendritic Cells in Patients With Type 1 Diabetes
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 22 Feb 2024
Price :
$35
*
At a glance
- Drugs DV 100 (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors DiaVacs
- 16 Feb 2024 Planned End Date changed from 1 Jan 2019 to 16 Feb 2024.
- 16 Feb 2024 Planned primary completion date changed from 1 Jul 2018 to 16 Feb 2024.
- 16 Feb 2024 Status changed from not yet recruiting to withdrawn prior to enrolment. ( Funding for study not procured.)